Literature DB >> 16433054

The haloperidol story.

Bernard Granger1, Simona Albu.   

Abstract

Haloperidol was synthesized on the 11th of February 1958 at the Janssen Laboratories, in Belgium. Soon after its synthesis and animal studies, which suggested to Paul Janssen and his colleagues that this butyrophenone drug would be of great interest as its action was similar but much more powerful than that of chlorpromazine, haloperidol was administered to humans at the Liege hospital. The subsequent clinical studies confirmed that this new drug was particularly active against delusions and hallucinations. The introduction of haloperidol in the United States of America was difficult for clinical and legal reasons. For many years, haloperidol had been widely used in western countries, until the introduction of "new antipsychotics."

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16433054     DOI: 10.1080/10401230591002048

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  12 in total

1.  Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy.

Authors:  John A Allen; Julianne M Yost; Vincent Setola; Xin Chen; Maria F Sassano; Meng Chen; Sean Peterson; Prem N Yadav; Xi-ping Huang; Bo Feng; Niels H Jensen; Xin Che; Xu Bai; Stephen V Frye; William C Wetsel; Marc G Caron; Jonathan A Javitch; Bryan L Roth; Jian Jin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-24       Impact factor: 11.205

Review 2.  Haloperidol dosing strategies in the treatment of delirium in the critically ill.

Authors:  Erica H Z Wang; Vincent H Mabasa; Gabriel W Loh; Mary H H Ensom
Journal:  Neurocrit Care       Date:  2012-02       Impact factor: 3.210

Review 3.  The antipsychotic landscape: dopamine and beyond.

Authors:  Paul D Morrison; Robin M Murray
Journal:  Ther Adv Psychopharmacol       Date:  2018-01-23

Review 4.  Epigenetic signaling in schizophrenia.

Authors:  Daisuke Ibi; Javier González-Maeso
Journal:  Cell Signal       Date:  2015-06-26       Impact factor: 4.315

5.  The story of antipsychotics: Past and present.

Authors:  Chaitra T Ramachandraiah; Narayana Subramaniam; Manuel Tancer
Journal:  Indian J Psychiatry       Date:  2009 Oct-Dec       Impact factor: 1.759

Review 6.  Group II metabotropic glutamate receptors and schizophrenia.

Authors:  José L Moreno; Stuart C Sealfon; Javier González-Maeso
Journal:  Cell Mol Life Sci       Date:  2009-08-26       Impact factor: 9.261

7.  Antifungal application of nonantifungal drugs.

Authors:  Marios Stylianou; Evgeny Kulesskiy; José Pedro Lopes; Margareta Granlund; Krister Wennerberg; Constantin F Urban
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

Review 8.  Genetic rodent models of brain disorders: Perspectives on experimental approaches and therapeutic strategies.

Authors:  Christopher M McGraw; Christopher S Ward; Rodney C Samaco
Journal:  Am J Med Genet C Semin Med Genet       Date:  2017-09       Impact factor: 3.908

Review 9.  Association Between Antipsychotic Medication Use and Diabetes.

Authors:  Richard I G Holt
Journal:  Curr Diab Rep       Date:  2019-09-02       Impact factor: 4.810

Review 10.  Comprehensive Psychopathological Assessment Based on the Association for Methodology and Documentation in Psychiatry (AMDP) System: Development, Methodological Foundation, Application in Clinical Routine, and Research.

Authors:  Rolf-Dieter Stieglitz; Achim Haug; Erdmann Fähndrich; Michael Rösler; Wolfgang Trabert
Journal:  Front Psychiatry       Date:  2017-04-07       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.